INTRODUCTION
============

Antivenom is specific treatment for the majority of medically important scorpion stings (Bawaskar and Bawaskar, 2011). The main aim of antivenom therapy is to achieve a group of antibodies able to neutralize the toxins proteins of scorpion venom belonging to the dangerous species in a defined geographical area. These toxins have high specificity towards a wide range of ion channels, receptors and transporters.

The pharmacokinetic study of the behavior of dangerous scorpion venoms and antivenoms is essential. It is recognized that antivenom should contain suitable pharmacokinetic parameters and be distributed rapidly to the tissues to neutrilize distributed toxins. The effectiveness in serum therapy also depends on potency of the antivenom, route of administration, elapsed-time between sting and antivenom administration times and prescribed dosage ([@CIT0012]; Vazquez et al, 2005). These understandings may lead to a precise definition of the antivenom quality and therapy applicable to different types of scorpion envenoming ([@CIT0031]). Furthermore, recently the multiple improvements for an effective antivenom therapy were reported with the use of smaller or recombinant antibody fragments ([@CIT0002], [@CIT0010]; [@CIT0003]; [@CIT0006]).

Experimental pharmacokinetic studies has been performed on *Leiurus quinquestriatus* , *Buthotus judaicus*, *Androctunus mauretanicus* maurtonicus, *Buthus occitanus tunetanus* and *Androctunus crassicauda* in rabbit, guinea pigs or rats ([@CIT0017]; [@CIT0015]; [@CIT0013]; [@CIT0030]; [@CIT0023]; [@CIT0008]). The pharmacokinetics studies were performed by using labeled venom ([@CIT0018]; [@CIT0016]; [@CIT0015]; [@CIT0013]; [@CIT0005]), or by measuring the concentration of toxin with ELISA ([@CIT0030] ;[@CIT0032]; [@CIT0023]; [@CIT0008]). The results of blood radioactivity level show two or three compartment model concerning to scorpion species and prescribed method.

The available polyvalent antivenom is produced by the Razi Vaccine and Serum Production and Research Institute against the 6 medically important scorpions: *Odonthubuthus doriae, Mesobuthus eupeus, Androctonus crassicauda, Buthotus (Hottentota)Saulcyi, Buthotus sach* and *H. lepturus* ([@CIT0025]). This product contains a dilution of the F(ab')~2~ fraction of equine immunoglobulins achieved after double saline precipitation and pepsin digestion ([Table 1](#T1){ref-type="table"}).

###### 

Some properties of the available scorpion antivenom (each 5ml/amp).

  **Tests**                               **Mean ±SD**
  --------------------------------------- -------------------
  pH                                      6.4 ±0.1
  Protein N (mg/ml)                       10.3 ±3.0
  Total Protein (g.%) Total solid (g.%)   6.5 ±1.8 9.8 ±2.6
  Albumin                                 non

At present, there is no definite study to guide Iranian clinicians on the choice of an appropriate route of administration. Therefore, this study was performed to assess the efficacy of intramuscular administration against one of the most dangerous scorpions in Iran, *H. lepturus* ([@CIT0021]) and further realization of the available treatment protocol in parallel with the performed study on other medically important scorpion, *Odonthubuthus doriae* ([@CIT0022]).

MATERIALS AND METHODS
=====================

Animals
-------

Male rats weighing 250-300gm were prepared from Razi Institute (Karaj, Tehran). The rats were housed in groups of three in PVC cages, and had free access to tap water and hard food pellets. The animals were kept at 23 ±2^o^C, and maintained at 12 hourly light/dark cycle, starting at 7am to 7pm.

All pharmacokinetic experiments were conducted in accordance with principles and guidelines of the "European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes. The Ethic Committee of the Jundishapur University, Ahvaz approved the design of the experiments.

Materials
---------

The CNBr-activated Sepharose and Sephadex G~50~ were prepared from Pharmacia (Uppsala, Sweden). CM-Sepharose was from Sigma (St Louis, MO, USA). Sodium dodecyl phosphate, Hydrogen peroxide, potassium phosphate buffer, sulforic acid, sodium sulfate, phenylenediamine and Trisbuffer were from Merck (Darmastadt, Germany). *H. lepturus* lyophilized venom and antivenom were presented by Razi institute. Venom was collected by electrical stimulation, extracted with water, freeze-dried and stored at -20^o^C until further use ([@CIT0026]).

Radioiodination of the venom and antivenom
------------------------------------------

Radioiodination of venom and antivenom were carried out using the chloramin-T method. This method specifically iodinates tyrosine residues in proteins forming a stable covalent protein-^131^I bond. The method is generally accepted to be mild enough so as not to affect the activity of the protein being labeled ([@CIT0011]; [@CIT0007]). Briefly, 0.3mCi (300μl) of ^131^I was added to 30μl of deionized H~2~O. Then the following solutions were added in this order: 3.5mg of venom in 300μl of 0.5M phosphate buffer, pH 7.2-7.4, 100μl of 6mg/ml chloramine-T; and 100μl of 6mg/ml sodium metabisulfite. Buffers were used to control the pH of solution for optimum efficiency of the proteins. To separate unincorporated ^131^I from the iodinated venom, a column packed with Sephadex G~50~ ([@CIT0027]) collected the labeled venom in 1ml fractions.

Biologic activity of radiolabelled venom
----------------------------------------

To identify the activity of the venom toxins being labeled, LD~50~, representing toxicity was assessed before and after radiolabelling in mice (18-20gm). Reed and Muenesh method was used to determine LD~50~ ([@CIT0029]). The radiolabelled solutions were made up at the rate of 1mg per ml. LD~50~ test was conducted by administration various amounts of radiolabelled venom in constant volume (0.2ml of saline solution).

Blood Sampling
--------------

21 male Wistar rats (250-300gm) have been divided to 7 groups (n=3) and 200μl of radiolabelled venom injected subcutaneously. For injections, the lower dorsum of rat, under ketamine anaesthesia, was wet shaved by a surgical blade and cloth dried. These groups were sampled at 10, 40, 60, 180, 210, 360 and 400min following SC administration of 5μg venom supplement with trace amounts of ^131^I. 18 male rats divided in 6 groups (n=3) were sampled at 5, 10, 40, 60, 120 and 360min following IM administration of 0.2ml labeled antivenom. The time course of venom and antivenom concentration in the plasma was followed by radioactivity. Samples of whole blood were collected in tubes containing ethylenediaminetetraacetic acid (EDTA) as anticoagulant (concentration 0.05M), immediately before and at regular time intervals after the end of the administrations. The concentration of scorpion ^131^I-labeled venom in plasma was determined following trichlroacetic acid (TCA) precipitation. Plasma samples (50μl) were added to 450 or 400μl of antivenom and then precipitated with 500μl of 20% (v/v) TCA. After a 30-60min incubation period, mixtures were centrifuged for 15min, and the radioactivity was determined in the pellet in a µ-counter (Pharmacia, Uppsala, Sweden). The results are presented as percent injected dose/ml blood. The percent radioactivity data were presented after conversion to ng/ml.

Determination of pharmacokinetic parameters
-------------------------------------------

The plasma concentration vs time data was subjected to a non-compartmental pharmacokinetic analysis to obtain an estimate of various pharmacokinetic parameters, such as total blood clearance (CL/F), distribution volume (Vd /F), area under the curve (AUC), and mean residence time (MRT). The area under the plasma concentration versus the time curve (AUC) was calculated using the linear trapezoidal rule with extrapolation to infinity. Cl/F, MRT and V~ss/F~ were calculated using the following non-compartmental equations ([@CIT0024]):

MRT = AUMC/AUC

Cl/F = Dose/AUC

V ss = Cl/F x MRT

AUMC (area under the first moment curve) is the area under the C plotted against *t* from time 0 to infinitive.

Statistical analysis
--------------------

All values were presented as mean ± standard deviation. The means were calculated from at least three separate experiments. The significance of the data was analyzed by the two-tailed unpaired or paired Students' test. The level of significance was considered at *P*\<0.05.

RESULTS
=======

Biologic activity of radiolabelled venom
----------------------------------------

The LD~50~ of radiolabelled venom was estimated 136 ±24.9µg/mice (6.8mg/kg). This value is not significant than determined LD~50~ following non radiolabelled venom test (5.81mg/kg or 116.2 ±27µg/mice) ([@CIT0025]).

Pharmacokinetics of the venom
-----------------------------

[Figure 1](#F1){ref-type="fig"} shows mean concentration-time curve and the corresponding pharmacokinetic parameters are noted in [Table 2](#T2){ref-type="table"}. The time to reach the maximal venom concentration in the blood, T~max~, was about 2hr and the apparent terminal half-life was 103min. The pharmacokinetics of the venom showed that after a relatively slow ascending phase, indicating a slow absorption and gradual distribution of scorpion toxins from central compartment, the toxin concentrations in plasma reached a steady-state plateau and a maximal value (C~max~) after T~max~ of 120min. Then the curve followed a rather slow bi-phasic decline, followed by a slow rate descending phase as seen in ascending phase ([Figure 1](#F1){ref-type="fig"}).

###### 

Phamacokinetic parameters of *H. lepturus* venom determined after SC injection of 5μg venom in rat.

  **Toxicokinetic parameters** **of venom**                    **Value** **(mean ±SEM)**   **CV%**
  ------------------------------------------------------------ --------------------------- ---------
  T ~max~ (min) [\*](#tf2-1){ref-type="table-fn"}              120±6                       5%
  C ~max~ (ng/ml) [\*\*](#tf2-2){ref-type="table-fn"}          7.86±2.1                    26%
  AUC[\*\*\*](#tf2-3){ref-type="table-fn"}~last~ (ng/min/ml)   2004.9±354                  17%
  T ~Half~ ~life~[^a^](#tf2-4){ref-type="table-fn"} (min)      103.25±18                   17%
  AUC ~INF~ (ng/min/ml)                                        2476.66±87                  3.5%
  Vd/F [^b^](#tf2-5){ref-type="table-fn"} (ml/kg)              14.9±2.1                    14%
  Cl/F [^c^](#tf2-6){ref-type="table-fn"} (ml/kg/min)          0.04±0.001                  2.5%
  MRT (min)                                                    **244.3**                   

The amount of time that venom is present at the maximum concentration in serum.

Cmax in **pharmacokinetics** refers to the maximum (or peak) concentration of venom in serum

AUC is the **area under** a plot of venom concentration-time profile

Elimination half-life

Apparent volume of distribution

Total (apparent, in case of venom) systemic clearance

MRT: mean resident residual time

![Plasma concentration time profile of venom after SC (subcutaneous) administration of 5μg of H*. lepturus* venom supplemented with trace amount of radiolabeled ^131^I to rat. Data are reported as means ±SEM (N = 3).](JVR-03-001-g001){#F1}

Pharmacokinetics of the antivenom
---------------------------------

Pharmacokinetic parameters of antivenom determined after an IM administration of antivenom by measurement of radioactivity method are shown in [Table 3](#T3){ref-type="table"}. AUC last and C~max~ were about 314 times higher and equivalent, respectively, in antivenom pharmacokinetic if compared with venom values. The T~max~ was reached earlier in antivenom (T~max~ = 25 vs 120min). Vd and MRT of antivenom were very higher than venom in the pharmacokinetic parameters obtained. The time course of antivenom concentration in plasma, determined by radioactivity measurements, showed a bi-exponential decline ([Figure 2](#F2){ref-type="fig"}), indicating that the antivenom was distributed into peripheral compartments with a terminal half-life (T~elimination\ half-life~) of 628.59min.

###### 

Phamacokinetic parameters of antivenom determined after IM administration of 0.2 ml of Razi polyvalent antivenom in rat.

  **Toxicokinetic parameters** **of antivenom**   **Value** **(mean ±SEM)**   **CV%**
  ----------------------------------------------- --------------------------- ---------
  T ~max~ (min)                                   25.34 ±2.758                10.88%
  C ~max~ (ng/ml)                                 8.1 ±0.16                   1.97%
  AUC ~last~ (ng/min/ml)                          629860 ±46609               7.40%
  T ~Half~ ~life~ (min)                           628.59 ±56.55               9%
  AUC ~INF~ (ng/min/ml)                           9779.1581 ±462.83           4.7%
  Vd/F (ml/kg)                                    666.66 ±85                  12%
  Cl/F (ml/kg/min)                                0.13 ±0.00973               7.4%
  MRT (min)                                       1292.87                     \-\-\--

![Plasma concentration-time profile of antivenom F(ab′)2 after IM (intramuscular) administration of 0.2ml of antivenom supplemented with trace amount of radiolabeled ^131^I to rat. Data are reported as means ±SEM (N=3).](JVR-03-001-g002){#F2}

DISCUSSION
==========

Currently, the scorpion sting victims in Iran, including those of *H. lepturus* sting, are treated in the most clinical centers with intramuscular administration of available antivenom instead of intravenous administration to avoid presumed effects of serum sickness. Therefore, the aim of this study was to determine the pharmacokinetics of *H. lepturus* venom and the available polyvalent antivenom to evaluate, or optimize the treatment protocols through intramuscular administration. In the present study, 5μg venom and 0.2ml antivenom were used. The adjusted dose of venom, as the result of a scorpion sting, was the same as the amount that was injected. Also, 0.2ml of the antivenom injection was adjusted to the rats, since in the current Iranian protocol, 2 vials of 5ml antivenom are recommended for an adult.

The data presented in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} show slow absorption and gradual distribution from blood into tissue and slow removing of venom. So it is likely that the release of venom from the site of injection was gradual. However, available antivenom had suitable speed in entering into the blood circulation and long domain of elimination. The CL~total~ of venom was 0/04ml/kg/min indicating the slow elimination of venom. This slow elimination is indicative of slow clearance of *H. lepturus* toxins in the performed experiment. This may have due to the experimental protocol designed which did not contain sufficient points at the end of experiments.

Considering T~max~ value, it is likely that venom absorption was slower than antivenom. So the maximal concentration of venom reached 1.5hr after antivenom. The main reason may be that SC administration route leads to slower absorption to reach central compartment (blood). In Borchani et al study a 33kDa *H. lepturus* venom protein endowed with a sphingomyelinase D was isolated and identified. This toxin has hemolytic and dermonecrotic activities and exceeds 6-fold the size of the scorpion venom toxins ([@CIT0004]). Therefore, it may be concluded that at least a fraction of this venom failed to diffuse and distribute readily from the vascular compartment to the various tissues ([@CIT0010]).

Antivenom has higher rate of entry into blood and more extended half. Furthermore, IM administration of the antivenom showed higher C~max~, higher AUC~last~ and an earlier T~max~. These parameters are indicative of a relatively faster uptake of the antivenom than venom. As predicted, the Vd/F value of antivenom was more than venom. So the antivenom possesses pharmacokinetic characteristics enabling it to distribute sufficiently to neutralize the distributed toxins to tissues. However, the highly significant difference between Vd/F and AUC values of antivenom than venom indicated thjat the venom and antivenom did not have sufficient possibility of interacting in tissues. This possibility is essential to alleviate the occurrence of common severe clinical signs following a *H. lepturus* sting with delay manifestations ([@CIT0028]; [@CIT0019]). This difference can be considered a reason for the lack of neutralizing activity observed *in vivo* ([@CIT0020]).

Surprisingly, *H. lepturus* venom with a slow rate clearance has significantly less T~half-life~ than reported value for the intramuscularly administered *O. doriae* venom ([@CIT0021]). The Vd indicating a extended distribution of the venom into tissues occurred in a large extravascular compartment. The Vd/F for the *H. lepturus* venom was greatly reducedl than *O. doriae* indicating a low distribution. This value was approximately 100x more for *O. doriae* ([@CIT0022]). This difference was not seen in the earlier studies ([@CIT0018]; [@CIT0016]; [@CIT0013]; [@CIT0030]; [@CIT0005]; [@CIT0008]; [@CIT0009]). The slow absorption of venom may be due to the high molecular weight toxins of this scorpion ([@CIT0004]). Thus it can be concluded that due to Vd the neutralization capacity of antivenom to react the *H. lepturus* toxins in tissues was less than that for *O. doriae* ([@CIT0022]). The pharmacokinetic parameters of the study conducted on *O. Doriae* showed an indistinguishable absorption rate (T~max~ = 120min for both) and a slower rate of distribution for *H. lepturus*. The AUC~last~ value (area under the concentration-time curve from zero time to complete removal) of *H. lepturus* venom was significantly less than that of the *O. doriae* value. This may indicate the reason for delay in occurrence of clinical manifestations following *H. lepturus* envenoming, and indicating that immediate treatment following *H. lepturus* sting is not an emergency situation. This delay is consistent with clinical conditions and a late occurance of sever envenoming ([@CIT0028]). However, the full spectrum of reasons behind this requires further investigation.

As presented in [Table 4](#T4){ref-type="table"}, neutralization capacities of the antivenom tested were expressed as the number of LD~50~ neutralization per one ml of serum. This potency was highest for *O. doriae* and *Buthotus salcyi* venom and moderate for *H. lepturus* venom. The potency of Iml refined antivenom in term of lethal doses neutralized was 7 mice LD~50~ for *H. lepturus* venom ([@CIT0025]) ([Table 4](#T4){ref-type="table"}). So 1 to 2 vials of antivenom administration (according to the current protocol), ranging from 5 to 10ml, should, suffice to neutralize the total amount of venom contained in the telson of any *H. lepturus* scorpion.

###### 

Mouse LD~50~ of venom neutralized by 1ml of Razi available antivenom (intravenous administration).

  **Scorpion species**                      **N. LD~50~**[\*](#tf4-1){ref-type="table-fn"}
  ----------------------------------------- ------------------------------------------------
  *Andrectonus crassicauda*                 10
  *Buthotus (Hottentona) saulcyi*           22
  *H. Lepturus* *Mesobuthus eupeus*         7 10
  *Odonthubuthus doriae* *Scorpio maurus*   37 5

Results of homologous tests

CONCLUSIONS
===========

Comparison of pharmacokinetic profiles of two Iranian scorpions showed that *O. doriae* venom had a much extended distribution in tissues as compared with the dangerous Iranian scorpian, *H. lepturus*. *O. doriae* study indicated that Razi antivenom offered a potential treatment of choice because of its fast absorption, ample distribution into the extracellular space and its prolonged MRT. In contrast, Vd for *H. lepturus* was 100-fold less and MRT was 244.3min. Immediate intramuscular administration of an adjusted dose of available antivenom had a favorable kinetic profile. If only kinetic profile is considered, this route would be appropriate when administered in referrals under 2hr. Furthermore, intramuscular administration does not appear to be appropriate for neutralization of *H. lepturus* envenomation.
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